EGFR and non-small cell lung carcinoma: Afatinib was first approved by the U.S. Food and Drug Administration on July 13, 2013, as a first-line treatment for NSCLC with an EGFR 19 exon deletion mutation or exon 21 L858R mutation.[12,13] Recently, the clinical activity of afatinib in NSCLC patients with rare EGFR mutations has been reported, and Yang et al[6,14] reported the results of LUX-Lung2, Lux-LunG3, and lux-Lung6 clinical trials of afatinib in patients with advanced NSCLC with non-classical mutations, which showed good reactivity to afatinib.